Health News Releases

  • Today August 24
December 04, 2020 10:20
Shape Therapeutics Unveils AAVid™ Capsid Discovery Platform and Identification of Novel Tissue-Specific AAV Variants, Solving a Fundamental Delivery Challenge in Gene Therapy
Shape Therapeutics, Inc. (ShapeTX), a next-generation gene therapy company with an industry-leading RNA targeting technology platform, announces today the unveiling of the AAVidTM capsid discovery pla
December 02, 2020 17:05
PierianDx Announces Expanded Partnership with Illumina to Support Cancer Genomic Reporting in Global Markets
PierianDx, the leading clinical genomics informatics company, today announced an expanded partnership with Illumina to enable PierianDx genomic reporting solutions for use with AmpliSeq™ for Illumina®
December 02, 2020 16:56
PCI Pharma Services Announces the Closing of the Majority Stake Acquisition by Kohlberg and Mubadala
PCI Pharma Services (“PCI” or “the Company”), a leading pharmaceutical and biopharmaceutical global supply-chain solutions provider, today announced the closing of the previously announced acquisition
December 02, 2020 12:37
LG Chem Life Sciences and TransThera Biosciences Announce FDA Clearance of IND for TT-01025, a SSAO/VAP-1 Inhibitor
LG Chem Life Sciences (“LG Chem”), a division of LG Chem, and TransThera Biosciences Co. Ltd. (“TransThera”), a clinical-stage biotechnology company based in Nanjing, China, announced today that U.S.
December 02, 2020 10:24
Rhizen Pharmaceuticals Announces US FDA Acceptance of its IND Application for RP7214 in SARS-CoV-2 Infection; Phase 1 Clinical Trial of RP7214 Set to Begin Early December 2020
Rhizen Pharmaceuticals, a clinical-stage oncology-focussed biopharmaceutical company, today announced the approval of its Investigational New Drug (IND) application by the U.S. Food and Drug Administr
December 02, 2020 09:08
Galderma Announces Top-line Results from Phase 2 Clinical Dose-Escalating Study with Azzalure® / Dysport® (abobotulinumtoxinA)
Galderma today announced top-line results from a Phase 2 study on the impact of dose escalation on the duration of effect and the efficacy and safety of a single dose of Dysport® (abobotulinumtoxinA)
December 01, 2020 14:10
Study Comparing Two Noninvasive Indicators of Fluid Responsiveness on Mechanically Ventilated Patients Finds Masimo PVi® Effective and Advantageous
Masimo (NASDAQ: MASI) announced today the findings of a study published in the Ain-Shams Journal of Anesthesiology in which Dr. Diaaeldin Aboelnile and colleagues at Ain-Shams University in Cairo, Egy
December 01, 2020 11:08
Takeda Completes Sale of Select OTC and Non-Core Assets to Celltrion in Asia Pacific
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of select products to Celltrion Inc. (“Celltrion”) f
November 26, 2020 17:10
Vifor Pharma supports Iron Deficiency Day 2020 to highlight global impact on health and gender inequality
Regulatory News: Vifor Pharma is marking the sixth anniversary of Iron Deficiency Day, focused on raising international awareness of the serious health impact of iron deficiency and iron deficiency
November 26, 2020 15:45
Fitbit and JMDC Sign Agreement to Appoint JMDC as Exclusive Distributor of Fitbit Premium for Enterprise Customers in Japan
Fitbit (NYSE: FIT) today announced that JMDC (TOKYO: 4483) will be the exclusive distributor of Fitbit Premium, Fitbit’s paid membership service, for enterprise customers in Japan. JMDC, one of Jap
November 26, 2020 09:48
MEDIROM Healthcare Technologies Inc. Announces Filing of Registration Statement for Proposed Initial Public Offering on NASDAQ
MEDIROM Healthcare Technologies Inc. (“MEDIROM”), the healthcare company which runs branded relaxation salons in Japan, today announced it has publicly filed a registration statement on Form F-1 with
November 25, 2020 11:25
Humanigen Australia Proprietary Limited Established to Facilitate Asia-Pacific Growth Plans
Humanigen, Inc. (NASDAQ: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidat
November 24, 2020 14:50
Patient Safety Movement Foundation Launches New Commitment Model Supporting Mission to Achieve Zero Preventable Patient Deaths By 2030
Every year, more than 4.8 million patients lose their lives to preventable medical errors worldwide. The Patient Safety Movement Foundation (PSMF), a global non-profit, is committed to achieving zero
November 20, 2020 16:00
Walgreens Reinvents Nation’s Largest Health and Wellbeing-centered Loyalty Program with myWalgreens to Offer Customers Many More Benefits
Walgreens today announced the launch of myWalgreens, a complete reinvention of its customer loyalty program to offer customers extensive new benefits, including the fastest same-day retail pickup offe
November 19, 2020 17:47
VFMCRP and Fresenius Kabi expand collaboration in nephrology in China with Veltassa® agreement
Regulatory News: Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Fresenius Kabi today announced an agreement to develop, register and distribute Veltassa® for the treatment of hyperkalemia i
November 19, 2020 13:31
Empagliflozin reduced the risk of first plus recurrent cardiovascular events in adults with type 2 diabetes and established cardiovascular disease in new analysis from the EMPA-REG OUTCOME® trial
Empagliflozin reduced the risk of total (first plus recurrent) cardiovascular events compared with placebo, when both were given on top of standard of care, in adults with type 2 diabetes and establis
November 18, 2020 19:10
PierianDx and Bench International Announce the Appointment of Mark McDonough as New CEO
PierianDx, the leading clinical genomics informatics company, and Bench International, a leading global executive search firm, jointly announce the appointment of Mark McDonough as Chief Executive Off
November 17, 2020 14:35
Study Investigates Effects of Patient Blood Management Program with Masimo SpHb®, Noninvasive, Continuous Hemoglobin Monitoring, on Postoperative Cancer Patients
Masimo (NASDAQ: MASI) announced today the findings of a study published in Blood Transfusion in which Dr. Lucia Merolle and colleagues at the Azienda USL-IRCCS of Reggio Emilia, Italy investigated the
November 17, 2020 10:50
Realize the Full Potential of the NextSeq 2000 with the Power of the P3 Reagent Kit
Illumina, Inc. (NASDAQ: ILMN) is further extending the reach of the NextSeq™ 2000 Sequencing System with the commercial availability of the P3 high-output flow cell. The P3 flow cell offers 1.1 billio
November 16, 2020 17:55
Boehringer Ingelheim receives positive CHMP opinion for use of Pradaxa® (dabigatran etexilate) for the treatment and prevention of venous thromboembolic events in children from birth to less than 18 years of age
Boehringer Ingelheim today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion on the proposed indication for Prad
November 16, 2020 09:22
Full Results From AFFIRM-AHF Study Show Ferinject® Significantly Reduces Hospitalizations After Acute Heart Failure in Patients With Iron Deficiency
Regulatory News: Vifor Pharma today presented the full results from the AFFIRM-AHF study at the 2020 American Heart Association (AHA) Scientific Sessions virtual congress. Simultaneously, results w
November 13, 2020 16:34
Final Results from the Phase 3 HELP Study™ Open-Label Extension Support TAKHZYRO® (lanadelumab-flyo) Injection as a Long-term Preventive Treatment Option in Patients with Hereditary Angioedema
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced the final results from the Phase 3 HELP (Hereditary Angioedema Long-term Prophylaxis) Study™ Open-label Extension (
November 12, 2020 13:40
One-Day Live International Medical Device School for Startups with 15 Global Experts Opens on Dec. 08
MediHeroes announces that International Medical Device School (IMDS) for Startups will be held virtually with a live presentation by the fifteen renowned global leaders from the MedTech industry on De
November 11, 2020 15:25
Healthcare at Home Launches Sciensus Rare to Connect Emerging Biotech and Large Pharma Companies With Rare Disease Patients in Europe and Beyond
Healthcare at Home today unveils a dedicated new rare disease medicines services business: Sciensus Rare. Sciensus Rare launches with two main aims: to ensure that patients and their families have
November 10, 2020 13:35
SpeeDx Partners with Nepean Hospital to Commercialise Respiratory Virus Host Biomarker Assay
SpeeDx Pty. Ltd., a developer of innovative molecular diagnostic solutions, has partnered with researchers from Nepean Blue Mountains Local Health District’s (NBMLHD) Nepean Hospital in an exclusive a
25 per page50 per page75 per page100 per page